Business Context and Reporting Period
Company: ANAVEX LIFE SCIENCES CORP.
Filing Type: Form 8-K (Current Report)
Date of Report: December 6, 2011
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. Key transaction metrics include:
- Gross Proceeds: $769,500
- Securities Issued: 615,600 units
- Price Per Unit: $1.25
- Transaction Costs: $57,000 (finders fees)
- Net Proceeds: $712,500 (calculated as gross proceeds minus fees)
Note: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or overall liquidity positions.
Material Changes and Transaction Details
The company executed a private placement of equity securities to two non-U.S. investors in an offshore transaction. The securities were issued under the registration exemptions of Regulation S and/or Section 4(2) of the Securities Act of 1933.
Unit Composition:
- 1 Share of Common Stock
- 0.5 Share Purchase Warrants
Warrant Terms:
- Exercise Price: $2.00 per share
- Expiration Date: December 6, 2012
- Conversion: One whole warrant is exercisable into one share of common stock.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the unregistered nature of the sale. The transaction was facilitated by a third party, resulting in a $57,000 finder's fee expense.
Investor Verification Checklist
- Verify the dilution impact of 615,600 new shares plus potential warrant exercises on existing shareholders.
- Confirm the use of proceeds, as the filing does not specify the intended allocation of the $712,500 net capital.
- Review the attached subscription agreement (Exhibit 10.1) for any restrictive covenants or specific investor rights.
- Check subsequent filings to determine if the warrants were exercised prior to the December 6, 2012 expiration.